Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

Benzinga11-07

At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial. The Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581301330?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/06/Wegovy.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-11-07 00:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581301330","market":"nz","top_or_hot":-1,"title":"Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits","media":"Benzinga","content":"<div>\n<p>At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial.\nThe Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHigher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-07 00:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial.\nThe Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits","article_id":"2581301330","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/06/Wegovy.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581301330","pubTimestamp":1762447500,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"At the ObesityWeek, Novo Nordisk A/S  presented new findings from the STEP UP phase 3b trial.The Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg dose of semaglutide compared to the 2.4 mg dose and a placebo for weight management in adults with obesity.It showed that Wegovy helps obese people lose an average of 21% of their body weight.The company on Thursday said Wegovy also enabled the participants to achieve treatment targets linked to a low risk of obesity-related complications.The results applied to both the approved semaglutide 2.4 mg dose and the investigational higher 7.2 mg dose.In the STEP UP sub-analysis, more people with obesity who received Wegovy achieved the target BMI of less than 27, as well as a waist-to-height ratio of less than 0.53.People treated with Wegovy who achieved both treatment targets reached healthy levels for two or more cardiovascular risk factors, including blood pressure, cholesterol, and blood sugar levels.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4081":"电力公用事业","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","CSII":"Cardiovascular Systems","EMA":"Emera Inc.","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4082":"医疗保健设备"},"translate_title":"较高剂量的Wegovy显示出减肥和心血管益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSII":1.5,"NVO":1,"EMA":1},"content_text":"At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial.\nThe Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg dose of semaglutide compared to the 2.4 mg dose and a placebo for weight management in adults with obesity.\nIt showed that Wegovy helps obese people lose an average of 21% of their body weight.\nThe company on Thursday said Wegovy also enabled the participants to achieve treatment targets linked to a low risk of obesity-related complications.\nThe results applied to both the approved semaglutide 2.4 mg dose and the investigational higher 7.2 mg dose.\nIn the STEP UP sub-analysis, more people with obesity who received Wegovy achieved the target BMI of less than 27, as well as a waist-to-height ratio of less than 0.53.\nSpecifically, 19.5% of those on semaglutide 7.2 mg and 13.2% on semaglutide 2.4 mg met these targets, compared to 0% for placebo.\nPeople treated with Wegovy who achieved both treatment targets reached healthy levels for two or more cardiovascular risk factors, including blood pressure, cholesterol, and blood sugar levels.\nOver half of the participants who achieved both BMI and waist-to-height ratio targets with Wegovy reached healthy levels for all four cardiovascular risk factors, indicating a low risk of cardiovascular disease.\nThe new, higher dose of Wegovy (semaglutide 7.2 mg), investigated in two STEP UP trials, is currently under review with the European Medicines Agency (EMA), in the U.K., and several other countries.\nIn the EU, Novo Nordisk expects a regulatory decision around the turn of the year. Novo Nordisk also expects to submit to the U.S. Food and Drug Administration.\nNovo Nordisk also presented new data from the OASIS 4 phase 3 trial of oral semaglutide 25 mg.\nResults showed that in the overall trial population, a higher percentage of participants with pre-diabetes at baseline achieved normal blood glucose (sugar) at week 64 in the semaglutide group versus placebo (71.1% versus 33.3%).\nParticipants treated with oral semaglutide 25 mg were more likely to achieve ≥15% body weight reduction, compared with those who received a placebo. Within the semaglutide group, more people who achieved ≥15% body weight reduction saw larger improvements than those with <15% weight reduction in blood pressure readings.\nReductions in levels of inflammatory marker C-reactive protein and in lipids (blood fats) were also observed.\nOral semaglutide 25 mg (Wegovy in a pill) is not FDA approved. In February, Novo Nordisk submitted a New Drug Application (NDA) for the once-daily pill formulation of Wegovy.\nThe FDA review of this NDA is anticipated to be completed by the end of this year. Currently, there are no approved oral formulations of a GLP-1 medicine for weight loss.\nNVO Price Action: Novo Nordisk shares were down 2.31% at $47.34 at the time of publication on Thursday. The stock is near its 52-week low of $45.05, according to Benzinga Pro data.\nRead Next:\nImage via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581301330","isCrawlerRequest":true}